AKE.PA Arkema Earnings Preview May 6, 2026

Arkema S.A. (AKE.PA) will report first-quarter earnings on May 6, 2026. Analysts expect earnings per share of $0.7850 and revenue of $2.18 billion. The specialty chemicals company faces headwinds from declining profitability and weak earnings growth. Last year, net income fell 82% while revenue dropped 5%. Investors will scrutinize whether management can stabilize margins and reverse negative trends. The stock trades at €61.95 with a market cap of $4.69 billion. Meyka AI rates AKE.PA with a grade of B, suggesting a neutral outlook. Understanding these earnings expectations helps investors assess Arkema’s operational recovery prospects.

Earnings Estimates and Expectations

Analysts project Arkema will deliver $0.7850 in earnings per share for the upcoming quarter. Revenue is estimated at $2.18 billion, representing steady performance in the specialty chemicals sector. These estimates matter because they set the bar for what constitutes a beat or miss.

Current EPS Forecast

The $0.7850 EPS estimate reflects modest profitability expectations. This compares to trailing twelve-month EPS of $0.51, suggesting analysts anticipate improvement. However, the company’s recent earnings history shows significant challenges. Last year, net income plummeted 82% year-over-year, indicating severe profitability pressure. The current estimate assumes Arkema can stabilize operations and recover from that dramatic decline.

Revenue Projection Analysis

The $2.18 billion revenue estimate signals relatively flat performance. Last year, Arkema’s revenue declined 5% to approximately $2.3 billion. This projection suggests the company may stabilize its top line after recent weakness. Revenue growth remains constrained by challenging market conditions in specialty chemicals. Investors should monitor whether Arkema can defend market share and pricing power in competitive segments.

Historical Performance and Earnings Trends

Arkema’s recent financial performance reveals a company under pressure. The specialty chemicals manufacturer has experienced significant earnings deterioration over the past year. Understanding this context is crucial for interpreting upcoming results.

Profitability Decline

Net income fell 82% in the most recent fiscal year, representing a dramatic earnings collapse. This decline far exceeds the 5% revenue drop, indicating severe margin compression. Operating income fell 28% while gross profit declined 17%. These metrics show the company struggled with both cost management and pricing. The effective tax rate jumped to 62%, further pressuring net earnings. This profitability crisis represents the biggest challenge Arkema faces heading into earnings season.

Segment Performance Concerns

Arkema operates four main segments: Adhesive Solutions, Advanced Materials, Coating Solutions, and Intermediates. Each segment faces different market dynamics. Adhesive Solutions serves construction and packaging markets, both cyclically sensitive. Advanced Materials and Coating Solutions depend on automotive and industrial demand. Intermediates face commodity-like pricing pressure. Management commentary on segment trends will be critical for assessing recovery prospects.

Cash Flow Deterioration

Operating cash flow declined 13% while free cash flow fell 5%. The company maintains a dividend yield of 5.8%, supported by €3.60 per share in annual dividends. However, weak cash generation raises questions about dividend sustainability. Investors should listen for management guidance on capital allocation and potential dividend adjustments.

Key Metrics to Watch During Earnings

Several important metrics will determine whether Arkema beats or misses expectations. Investors should focus on these specific areas during the earnings call and guidance.

Margin Recovery Signals

Gross margin stands at 17.8%, down from historical levels. Operating margin sits at 3.9%, reflecting operational stress. Management must demonstrate concrete steps to restore profitability. Watch for commentary on cost reduction initiatives, pricing actions, and product mix improvements. Any indication of margin stabilization would be positive for the stock.

Debt and Liquidity Position

Arkema carries significant debt with a debt-to-equity ratio of 0.89. Net debt to EBITDA stands at 2.73 times, indicating moderate leverage. The company maintains €2.2 billion in working capital, providing operational flexibility. Management should address refinancing plans and debt reduction targets. Interest coverage of 2.8 times leaves limited room for further deterioration.

Segment Revenue Breakdown

Analysts will scrutinize revenue performance by segment. Adhesive Solutions and Coating Solutions typically represent the largest revenue contributors. Advanced Materials offers higher margins but faces cyclical demand. Intermediates provides stable cash flow but limited growth. Detailed segment guidance will help investors assess which areas are recovering and which remain challenged.

What Could Cause a Beat or Miss

Arkema’s earnings surprise will depend on several factors. Understanding these drivers helps investors anticipate potential outcomes.

Factors Supporting a Beat

Strong demand in automotive and construction markets could drive revenue above estimates. Successful pricing actions in specialty segments might expand margins. Cost reduction programs could deliver unexpected savings. Favorable currency movements, particularly euro strength, could boost reported results. Any positive commentary on market stabilization would likely trigger positive market reaction.

Factors Supporting a Miss

Weakness in European construction markets could pressure Adhesive Solutions revenue. Automotive demand slowdown would hurt Advanced Materials sales. Commodity chemical price declines could compress Intermediates margins. Higher-than-expected raw material costs would pressure profitability. Negative guidance on market conditions would likely disappoint investors. The company’s recent earnings collapse suggests downside risks remain elevated.

Analyst Consensus Considerations

Current analyst consensus reflects cautious optimism. The B+ rating from Meyka AI suggests neutral positioning. Strong Buy ratings on DCF valuation contrast with Strong Sell ratings on valuation multiples. This mixed sentiment indicates uncertainty about Arkema’s recovery trajectory. Earnings results that clarify management’s turnaround strategy could shift consensus significantly.

Final Thoughts

Arkema’s May 6 earnings report will test investor confidence in the company’s recovery. Analysts expect $0.7850 EPS and $2.18 billion revenue, representing modest improvement from recent weakness. However, the 82% net income decline last year and 28% operating income drop create a challenging comparison. Meyka AI rates AKE.PA with a grade of B, reflecting neutral fundamentals and mixed valuation signals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should focus on margin recovery signals, segment performance, and management guidance on market stabilization. The stock’s 5.8% dividend yield attracts i…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.